Join
Live feed
·
PRReleasevia Quantisnow
Surface Oncology Inc. logo

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort

ByQuantisnow·Wall Street's wire, on your screen.
SURF· Surface Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SURF (Surface Oncology Inc.) and more on Quantisnow.